For fiscal 2025, Knight has increased its financial guidance on revenues and now expects to generate between $410 million to $420 million in revenues up from $390 to $405 million. The adjusted EBITDA is expected to be approximately 13% of revenues. The increase in our revenues outlook is driven by the better performance in the first half of the year and the incremental revenues from the Sumitomo Transaction.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight Therapeutics announces CREXONT regulatory submission in Mexico
- Knight Therapeutics announces CREXONT NDS accepted for Health Canada review
- Knight Therapeutics closes acquisition of Paladin
- Knight Therapeutics Secures US$50 Million Credit Facility to Fuel Growth
- Knight Therapeutics closes $50M revolving credit facility